Bluejay Diagnostics, Inc. is a Delaware-incorporated healthcare diagnostics company traded on Nasdaq, focusing on medical device research, development, and product launch activities.

# Company Summary: Bluejay Diagnostics, Inc.

**Overview:**
- Bluejay Diagnostics, Inc. is a company incorporated in Delaware with I.R.S. Employer Identification No. 47-3552922.
- The company’s principal executive offices are located at 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.
- Its common stock is traded on the Nasdaq Stock Market LLC under the symbol **BJDX**.

**Business Focus:**
- The specific business activities and operations of Bluejay Diagnostics are not explicitly detailed in the provided document. However, from the context, especially the executive backgrounds and industry references, it appears to operate within the medical device or healthcare diagnostics sector.
- The company has engaged in healthcare consulting and product launch activities, as evidenced by the experience of its founders and current officers.
- The company has research and development facilities and laboratories, including agreements with NanoHybrids, LLC for R&D services.

**Size and Financials:**
- As of April 28, 2025, the company has **1,494,167 shares of common stock outstanding**.
- The aggregate market value of voting stock held by non-affiliates was approximately **$1,700,000** as of June 30, 2024.
- Revenue, net income, number of customers, or employee counts are not directly provided in the excerpt.

**Management and Board:**
- The company has a Board of Directors with the following members:
  - Indranil (Neil) Dey: President, CEO, and Director.
  - Dr. Jason Cook: Chief Technology Officer.
  - Douglas C. Wurth: Director and Chairman of the Board.
  - Svetlana Dey: Director.
  - Donald R. Chase: Director.
  - Fred S. Zeidman: Director.
  - Gary Gemignani: Director.
- Neil Dey, the President and CEO, has extensive experience in medical diagnostics and healthcare consulting, with prior roles in business development and product commercialization in the medical device industry.
- The company employs a small team, with specific staffing numbers not disclosed.

**Recent Developments:**
- The Board composition is changing, with Gary Gemignani not seeking re-election in the 2025 annual meeting, and the Board will be reduced from six to five members.
- The company has no publicly disclosed revenue or income figures in the provided document.

**Additional Notes:**
- The company’s securities are registered on Nasdaq, and it is classified as a smaller reporting company and emerging growth company.
- The company has conducted multiple meetings and has active committees overseeing financial reporting, governance, and executive compensation.

*Note: The document primarily contains legal, governance, and executive compensation details. Specific operational or financial performance metrics such as revenues, customer counts, employee numbers, or net income are not included in the provided excerpt.*

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on developing rapid diagnostic tests using its proprietary Symphony technology platform for critical care environments.

# Bluejay Diagnostics, Inc. Overview

## Company Description
Bluejay Diagnostics, Inc. is a medical diagnostics company specializing in the development of rapid diagnostic tests. The company leverages its proprietary **Symphony technology platform** to create tests that utilize whole blood for quicker diagnostic results, mainly aimed at critical care environments such as Intensive Care Units (ICUs) and Emergency Rooms (ERs).

## Key Product
- **Symphony IL-6 Test**: This is Bluejay's first product focused on monitoring disease progression in critical care settings. The test evaluates **IL-6**, a clinically recognized inflammatory biomarker, to help assess infection severity and inflammation, crucially aiding in the treatment of conditions such as sepsis.

## Future Developments
- Plans to expand the Symphony platform to include additional biomarker tests, specifically targeting cardiac biomarkers like **hsTNT** (high-sensitivity Troponin T) and **NT pro-BNP** (N-terminal pro b-type Natriuretic Peptide).

## Market Opportunity
- Targets a niche within the global in vitro diagnostics (IVDs) market, addressing **sepsis, cardio-metabolic diseases, cancer**, and other conditions necessitating rapid diagnostics.
- Aims to serve a substantial segment of critical care providers, focusing initially on large critical care hospitals in the United States.

## Business Model
- **Attractive Financing Options**: Bluejay intends to offer flexible financing for the Symphony device, minimizing upfront capital expenditure for clients.
- **Recurring Revenue**: The company anticipates generating most of its revenue from the sale of single-use diagnostic test cartridges as usage increases.
- **Expansion of Diagnostic Products**: As adoption of the Symphony platform grows, Bluejay plans to enhance its test offerings, thereby increasing annual revenue per customer.

## Company Size and Financials
- **Employees**: As of March 28, 2024, Bluejay employs **10 full-time staff**.
- **Revenue**: The company currently has **no product revenue** as it is still in the development phase of its Symphony products.
- **Net Losses**: Bluejay has reported net losses of approximately **$9.8 million** and **$9.3 million** for the years ending December 31, 2023, and 2022, respectively.
  
## Funding and Operations
- The company's funding has primarily come from equity financing efforts, including its **initial public offering (IPO)** in November 2021 and a series of public and direct offerings in 2023.
- Despite securing funding, the company anticipates that it will run out of available cash by **Q3 2024**, necessitating further capital raising efforts.
  
## Regulatory Status
- The Symphony platform products have yet to receive regulatory clearance from the FDA. Bluejay is currently conducting clinical studies aimed at supporting FDA submissions for their tests.

In summary, Bluejay Diagnostics is focused on advancing the rapid diagnostics sector through innovative technology aimed specifically at critical care, with significant room for growth and development once regulatory hurdles are overcome.

Bluejay Diagnostics, Inc.

10-K / April 29, 2025

10-K / March 28, 2024

10-K / April 29, 2025

Company Summary: Bluejay Diagnostics, Inc.